This assessment of a sigma-1 receptor drug similar to AVXL's 2-73 should really put the nail in the coffin on that class of drugs. No wonder the market doesn't view their pipeline as holding promise.
As we progress towards late August results, the market will realize that NTRP may be the only game in town in the Alzheimer's arena.
Market Data 
Markets 
AI
